Objective:

To evaluate the effectiveness of the 2025-2026 COVID-19 vaccine in providing short-term protection against medically attended COVID-19 among immunocompetent adults.

Approach:

• Study Design: A test-negative case-control study using data from the VISION Network, including 253 ED/UC sites and 179 hospitals across 7 US states.
• Population: Patients aged 18 years or older who sought care for COVID-19-like illness and underwent SARS-CoV-2 testing from September 3 to December 31, 2025.
• Vaccine Effectiveness Estimation: Compared the odds of vaccination among cases (positive SARS-CoV-2 test) vs controls (negative test), adjusting for age, sex, race, ethnicity, calendar time, and geographic region.

Key Findings:

• Vacineftswmd50gO19Urhplz6y483b

Interpretation:

Limitations:

• Somepatinyhvugcrfld19bwz

Conclusion:

The study highlights the short-term effectiveness of the 2025-2026 COVID-19 vaccine in a specific population during the early respiratory virus season.

Sources:

• CDC VISION Network Study